Merck Institute for Science Education

Recent papers from Merck Institute for Science Education

1. Abstract CT142: Reducing nausea and vomiting while maintaining the full potential for efficacy with spevatamig, a CLDN18.2xCD47 bispecific antibodyCancer Research · 2026
2. Abstract CT144: Pharmacokinetics of spevatamig (PT886), a bispecific antibody targeting CLDN18.2 and CD47, in patients with advanced gastrointestinal cancers as monotherapy or combination therapyCancer Research · 2026
3. Abstract CT057: Preliminary results from the first-in-human study of MK-2010, a PD-1×VEGF bispecific antibodyCancer Research · 2026
4. Abstract CT143: Resolved hematological toxicities associated with anti-CD47 agents using a bispecific design involving an optimized anti-CD47 arm: A clinical proof of concept studyCancer Research · 2026
5. Abstract 7902: Analytical accuracy and clinical performance of the OncoMate MSI Dx Analysis System in a subset of KEYNOTE-775 endometrial carcinoma classified as MSS (not MSI-H) by the companion diagnosticCancer Research · 2026
6. Abstract 6290: Next-generation sequencing utilization among U.S. Veterans with metastatic cancer in the VA Healthcare System.Cancer Research · 2026
7. Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 StudyCancer Research Communications · 2026
8. Abstract PS2-06-17: Olaparib Use and gBRCA Testing among HER2-Negative Early-Stage Breast Cancer Patients in the United States Community Oncology SettingClinical Cancer Research · 2026
9. A mitochondrial amidoxime-reducing component 1 (mARC1) A168T amino acid substitution does not confer protection from MASH and fibrosis in multiple mouse models of chronic liver diseaseBiochemical Journal · 2025
10. INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaClinical Cancer Research · 2025
11. Long-term safety and tolerability of frespaciguat: the INSIGNIA-PAH extensionEuropean Respiratory Journal · 2025
12. Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced MelanomaClinical Cancer Research · 2025
13. Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or LymphomasClinical Cancer Research · 2025
14. SMARCA4 Loss Increases RNA Polymerase II Pausing and Elevates R-Loops to Inhibit BRCA1-Mediated Repair in Ovarian CancerCancer Research · 2025
15. Achieving Acceleration to First-in-Human: MSD’s Learnings on Platform Method Validation StrategymAbs · 2025
16. Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or LymphomasClinical Cancer Research · 2025
17. Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1–Pretreated Metastatic Non–Small Cell Lung Cancer and Metastatic Cutaneous MelanomaClinical Cancer Research · 2024
18. Autofluorescence Virtual Staining System for H&E Histology and Multiplex Immunofluorescence Applied to Immuno-Oncology Biomarkers in Lung CancerCancer Research Communications · 2024
19. Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung CancerClinical Cancer Research · 2024
20. Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial CarcinomaClinical Cancer Research · 2024